Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3681 participants.
Also called NCT01854918
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,681 participants
- Sponsor
- Registry
-
NCT01854918 -
2012-004357-83
-
- Other papers using this trial's data
- Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus
- Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hong Kong SAR China, Hungary, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01854918. Randomized; no masking; primary purpose treatment. Start 2013-04-23 (actual); primary completion 2018-05-31 (actual). Results posted on 2019-06-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
- Acronym
- OSLER-2
- Condition
- Hyperlipidemia and Mixed Dyslipidemia
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Standard of Care
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01854918- Content hash
35dc86fd66bc4a94bb127a42933b6bd9721ec9583f35155d33566963b59d17d0